Fluvastatin Sodium

氟伐他汀钠

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameFluvastatin Sodium
Drug Alias Namefluvastatine氟伐他停钠Fluindostatin sodium氟伐他丁钠fluvastatinum +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHealthy AgingInflammation +[11] 
Global Approved IndicationsHypercholesterolemiaDyslipidemias
Approved Indications in ChinaHypercholesterolemiaDyslipidemias
Original Approved Country/TerritoryUnited States
Original Approved Date1993/12/31
Country/TerritoryUnited StatesGermanySwitzerland +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesYuyu PharmaSandoz IncNovartis Ringaskiddy Ltd
Inactive CompaniesUniversity Of California San FranciscoMartin-Luther-Universitat Halle-WittenbergLeipzig University +[5] 
Active IndicationsHypercholesterolemiaDyslipidemiasAtherosclerosis
Inactive IndicationsHeterozygous familial hypercholesterolemiaHealthy AgingInflammation +[8] 

Other Information

ATC CodeC10AA04
Related LinksWikipediaDrugBankKEGG